Cargando…

Lactoferrin and Human Neutrophil Protein (HNP) 1–3 Levels During the Neonatal Period in Preterm Infants

Antimicrobial polypeptides (APPs) are part of the innate immune system, but their specific role in the context of preterm birth is not yet understood. The aim of this investigation was to determine the systemic expression of APPs, i.e., lactoferrin (LF) and human neutrophil protein (HNP) 1–3 in pret...

Descripción completa

Detalles Bibliográficos
Autores principales: Faust, Kirstin B., Moser, Katja, Bartels, Maren, Fortmann, Ingmar, Hanke, Kathrin, Wieg, Christian, Stichtenoth, Guido, Göpel, Wolfgang, Herting, Egbert, Härtel, Christoph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9364083/
https://www.ncbi.nlm.nih.gov/pubmed/35967550
http://dx.doi.org/10.3389/fped.2022.909176
_version_ 1784765074210029568
author Faust, Kirstin B.
Moser, Katja
Bartels, Maren
Fortmann, Ingmar
Hanke, Kathrin
Wieg, Christian
Stichtenoth, Guido
Göpel, Wolfgang
Herting, Egbert
Härtel, Christoph
author_facet Faust, Kirstin B.
Moser, Katja
Bartels, Maren
Fortmann, Ingmar
Hanke, Kathrin
Wieg, Christian
Stichtenoth, Guido
Göpel, Wolfgang
Herting, Egbert
Härtel, Christoph
author_sort Faust, Kirstin B.
collection PubMed
description Antimicrobial polypeptides (APPs) are part of the innate immune system, but their specific role in the context of preterm birth is not yet understood. The aim of this investigation was to determine the systemic expression of APPs, i.e., lactoferrin (LF) and human neutrophil protein (HNP) 1–3 in preterm infants in the period of highest vulnerability for infection and to correlate these biomarkers with short-term outcome. We therefore conducted a prospective two-center study including plasma samples of 278 preterm infants and 78 corresponding mothers. APP levels were analyzed on day 1, 3, 7, and 21 of life via enzyme-linked immunosorbent assay (ELISA). The levels of LF and HNP1–3 remained stable during the first 21 days of life and were not influenced by maternal levels. Elevated APP levels were found at day 1 in infants born to mothers with amniotic infection syndrome (AIS vs. no AIS, mean ± SD in ng/ml: LF 199.8 ± 300 vs. 124.1 ± 216.8, HNP 1–3 16,819 ± 36,124 vs. 8,701 ± 11,840; p = 0.021, n = 179). We found no elevated levels of APPs before the onset of sepsis episodes or in association with other short-term outcomes that are in part mediated by inflammation such as necrotizing enterocolitis (NEC) or retinopathy of prematurity (ROP). Interestingly, infants developing bronchopulmonary dysplasia (BPD) showed higher levels of HNP1–3 on day 21 than infants without BPD (13,473 ± 16,135 vs. 8,388 ± 15,938, n = 111, p = 0.008). In infants born without amniotic infection, levels of the measured APPs correlated with gestational age and birth weight. In our longitudinal study, systemic levels of LF and HNP 1–3 were not associated with postnatal infection and adverse short-term outcomes in preterm infants.
format Online
Article
Text
id pubmed-9364083
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93640832022-08-11 Lactoferrin and Human Neutrophil Protein (HNP) 1–3 Levels During the Neonatal Period in Preterm Infants Faust, Kirstin B. Moser, Katja Bartels, Maren Fortmann, Ingmar Hanke, Kathrin Wieg, Christian Stichtenoth, Guido Göpel, Wolfgang Herting, Egbert Härtel, Christoph Front Pediatr Pediatrics Antimicrobial polypeptides (APPs) are part of the innate immune system, but their specific role in the context of preterm birth is not yet understood. The aim of this investigation was to determine the systemic expression of APPs, i.e., lactoferrin (LF) and human neutrophil protein (HNP) 1–3 in preterm infants in the period of highest vulnerability for infection and to correlate these biomarkers with short-term outcome. We therefore conducted a prospective two-center study including plasma samples of 278 preterm infants and 78 corresponding mothers. APP levels were analyzed on day 1, 3, 7, and 21 of life via enzyme-linked immunosorbent assay (ELISA). The levels of LF and HNP1–3 remained stable during the first 21 days of life and were not influenced by maternal levels. Elevated APP levels were found at day 1 in infants born to mothers with amniotic infection syndrome (AIS vs. no AIS, mean ± SD in ng/ml: LF 199.8 ± 300 vs. 124.1 ± 216.8, HNP 1–3 16,819 ± 36,124 vs. 8,701 ± 11,840; p = 0.021, n = 179). We found no elevated levels of APPs before the onset of sepsis episodes or in association with other short-term outcomes that are in part mediated by inflammation such as necrotizing enterocolitis (NEC) or retinopathy of prematurity (ROP). Interestingly, infants developing bronchopulmonary dysplasia (BPD) showed higher levels of HNP1–3 on day 21 than infants without BPD (13,473 ± 16,135 vs. 8,388 ± 15,938, n = 111, p = 0.008). In infants born without amniotic infection, levels of the measured APPs correlated with gestational age and birth weight. In our longitudinal study, systemic levels of LF and HNP 1–3 were not associated with postnatal infection and adverse short-term outcomes in preterm infants. Frontiers Media S.A. 2022-07-27 /pmc/articles/PMC9364083/ /pubmed/35967550 http://dx.doi.org/10.3389/fped.2022.909176 Text en Copyright © 2022 Faust, Moser, Bartels, Fortmann, Hanke, Wieg, Stichtenoth, Göpel, Herting and Härtel. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pediatrics
Faust, Kirstin B.
Moser, Katja
Bartels, Maren
Fortmann, Ingmar
Hanke, Kathrin
Wieg, Christian
Stichtenoth, Guido
Göpel, Wolfgang
Herting, Egbert
Härtel, Christoph
Lactoferrin and Human Neutrophil Protein (HNP) 1–3 Levels During the Neonatal Period in Preterm Infants
title Lactoferrin and Human Neutrophil Protein (HNP) 1–3 Levels During the Neonatal Period in Preterm Infants
title_full Lactoferrin and Human Neutrophil Protein (HNP) 1–3 Levels During the Neonatal Period in Preterm Infants
title_fullStr Lactoferrin and Human Neutrophil Protein (HNP) 1–3 Levels During the Neonatal Period in Preterm Infants
title_full_unstemmed Lactoferrin and Human Neutrophil Protein (HNP) 1–3 Levels During the Neonatal Period in Preterm Infants
title_short Lactoferrin and Human Neutrophil Protein (HNP) 1–3 Levels During the Neonatal Period in Preterm Infants
title_sort lactoferrin and human neutrophil protein (hnp) 1–3 levels during the neonatal period in preterm infants
topic Pediatrics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9364083/
https://www.ncbi.nlm.nih.gov/pubmed/35967550
http://dx.doi.org/10.3389/fped.2022.909176
work_keys_str_mv AT faustkirstinb lactoferrinandhumanneutrophilproteinhnp13levelsduringtheneonatalperiodinpreterminfants
AT moserkatja lactoferrinandhumanneutrophilproteinhnp13levelsduringtheneonatalperiodinpreterminfants
AT bartelsmaren lactoferrinandhumanneutrophilproteinhnp13levelsduringtheneonatalperiodinpreterminfants
AT fortmanningmar lactoferrinandhumanneutrophilproteinhnp13levelsduringtheneonatalperiodinpreterminfants
AT hankekathrin lactoferrinandhumanneutrophilproteinhnp13levelsduringtheneonatalperiodinpreterminfants
AT wiegchristian lactoferrinandhumanneutrophilproteinhnp13levelsduringtheneonatalperiodinpreterminfants
AT stichtenothguido lactoferrinandhumanneutrophilproteinhnp13levelsduringtheneonatalperiodinpreterminfants
AT gopelwolfgang lactoferrinandhumanneutrophilproteinhnp13levelsduringtheneonatalperiodinpreterminfants
AT hertingegbert lactoferrinandhumanneutrophilproteinhnp13levelsduringtheneonatalperiodinpreterminfants
AT hartelchristoph lactoferrinandhumanneutrophilproteinhnp13levelsduringtheneonatalperiodinpreterminfants